Sergey Viktorovich Chepur

Sergey Viktorovich Chepur

Auto-generated profile, based on publicly available information

Sergey Viktorovich Chepur

State research testing Institute of military medicine of the Ministry of defense of the Russian Federation

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2021 in Antibiot Khimioter = Antibiotics and Chemotherapy
Verified
Journal Article
Closed access
PDF file
ASA. U. Sabitov
A. U. Sabitov
OKO. P. Kovtun
O. P. Kovtun
NBN. A. Batskalevich
N. A. Batskalevich
OMO. V. Maltsev
O. V. Maltsev
KZK. V. Zhdanov
K. V. Zhdanov
ASA. V. Stepanov
A. V. Stepanov
The aimof the study was to carry out meta-analysis of randomized controlled trials in order to combine the results of clinical trials on Triazavirin®(Riamilovir) efficacy in the etiotropic therapy of acute respiratory viral infection.Materials and methods.The studies included 435 patients with a confirmed diagnosis of acute respiratory viral infection or ARVI (with laboratory confirmed absence of influenza virus antigens). The research was carried out in 27 centers. In studies, patients were divided into 3 groups in a 1:1:1 ratio (a total of 145 people per group). Each study included a group taking 100 mg of the medication 5 times a day, a group taking 250 mg of the medication 3 times a day and a placebo 2 times a day, as well as a group taking a placebo 5 times a day. The analysis was carried out in accordance with the PRISMA principles regarding the quality of information presentation on the results of systematic reviews and meta-analyzes of works evaluating the effects of medical interventions.Results. The conducted meta-analysis showed that the use of Triazavirin®(Riamilovir) has a statistically significantly effects on the severity of clinical symptoms in patients with ARVI. The performed meta-analysis confirmed reliable associations between the use of Triazavirin®(Riamilovir) in both doses and the chance of a persistent improvement in clinical symptoms on the 5thday of therapy. The meta-analysis also confirmed the statistical significance of the clinical effects of Riamilovir by such indicators as the area under the curve «point on the scale showing the severity of the condition in a patient with ARVI in relation to time», the proportion of patients with complete alleviation of all symptoms by the end of the 5th day from the start of therapy.Conclusion.The clinical trials proved that the use of Triazavirin®(Riamilovir) is effective both in the initial and in the late stages of the disease, therefore, the drug can be used in the initial therapy of adult patients with respiratory diseases of viral etiology.

30 August 2021 in Antibiot Khimioter = Antibiotics and Chemotherapy
Verified
Journal Article
Closed access
PDF file
ASA. U. Sabitov
A. U. Sabitov
OKO. P. Kovtun
O. P. Kovtun
NBN. A. Batskalevich
N. A. Batskalevich
НЛН. И. Львов
Н. И. Львов
KZK. V. Zhdanov
K. V. Zhdanov
ASA. V. Stepanov
A. V. Stepanov
The aim of the study was to carry out a meta-analysis of randomized clinical trials in order to combine the results of clinical trials on Triazavirin® (Riamilovir) efficacy in etiotropic therapy of influenza.Materials and methods. The analysis was carried out in accordance with the PRISMA principles regarding the quality of information presentation on the results of systematic reviews and meta-analyzes of works assessing medical interventions. The study included 471 patients with a confirmed diagnosis of influenza (with laboratory confirmed presence of influenza virus antigens).Results. The conducted meta-analysis showed that the use of Triazavirin® (Riamilovir) has a statistically significant effect on the severity of clinical symptoms in patients with influenza, therefore Riamilovir can be used in the initial therapy of adult patients with influenza.Conclusion. Clinical studies have shown that the use of Triazavirin® (Riamilovir) is effective both in the initial and late stages of the disease, and therefore Riamilovir can be used in the treatment of adult patients with respiratory diseases of viral etiology, in particular, those diagnosed with influenza. The meta-analysis of the collected data showed that therapy with Triazavirin® (Riamilovir) has statistically significant advantages in various aspects both in comparison with the placebo group and with the Tamiflu® (Oseltamivir) group.

17 January 2012 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
IFI. V. Fateev
I. V. Fateev
VBV. N. Bykov
V. N. Bykov
SCS. V. Chepur
S. V. Chepur
LPL. A. Pokrovskaya
L. A. Pokrovskaya
NSN. I. Shemeleva
N. I. Shemeleva
IAI. I. Alekseeva
I. I. Alekseeva

1 January 2021 in CLINICAL AND EXPERIMENTAL MORPHOLOGY
Verified
Journal Article
Closed access
SCS.V. Chepur
S.V. Chepur
MTM.A. Tyunin
M.A. Tyunin
VMV.A. Myasnikov
V.A. Myasnikov
IAI.I. Alekseeva
I.I. Alekseeva
OVO.V. Vladimirova
O.V. Vladimirova
ASA.V. Smirnova
A.V. Smirnova
Introduction. Amid the pandemic of the new coronavirus infection COVID-19, experimental models for screening both newly developed vaccines and drugs, and the already registered active pharmaceutical in-gredients tested for new indications are in high demand. The registration of changes in biometric and mor-phological parameters that are significant for the investigative pathology can be an optimal screening tool for antiviral drugs and vaccines to treat COVID-19. In this regard, the purpose of this study was to describe the changes over time of organ and tissue changes using a biological model of a SARS-CoV-2-associated infection in the golden hamsters Mesocricetus auratus. Materials and methods. We performed the study in golden hamsters Mesocricetus auratus weighing 80–100 g. The animals were infected through intranasal administration of a culture of SARS-CoV-2 virus containing 4 × 104 TCID50/mL. We recorded the animals’ weight before the infection and during the next 14 days and measured the specific gravity of the internal organs and the degree of their moisture saturation on days 3, 7, and 14 after the infection. Additionally, tissue samples were fixed in 10% neutral formalin; the preparation of histological specimens was performed according to the standard procedure. Statistical data processing was carried out using non-parametric tests. Results. In the model of SARS-CoV-2 infection in Mesocricetus auratus, we observed the manifestation of the infectious disease after 3 days. The most pronounced pathological changes in the overall health status of the animals and in the histology of internal organs were seen 7 days after the infection. We determined the weight loss and significant deviations in gravimetric coefficients of lungs, heart, spleen, and kidneys to be the indicators revealing the infectious disease course changes over time. Histologic evaluation showed typical changes in the SARS-CoV-2-associated visceral damage: the formation of polymorphonuclear cell infiltrates in the lung interalveolar septa and patchy dystrophic changes in the neurocytes of the brain screen-type centers with the demyelination of the commissural nerve guides. The detected pathological manifestations corresponded in time to an increase in the virus replicative activity in the lungs. Conclusion. The experimental model of the SARS-CoV-2-associated infection in golden hamsters Mesocricetus auratus can be recommended for screening experimental (preclinical) studies of the promising drugs’ efficacy for pathogenetic and etiotropic therapy of COVID-19. Keywords: SARS-CoV-2, golden hamsters, morphometry, organ and tissue structural damage

21 October 2021 in Antibiot Khimioter = Antibiotics and Chemotherapy
Verified
Journal Article
Closed access
PDF file
SCS. V. Chepur
S. V. Chepur
ASA. V. Smirnova
A. V. Smirnova
AKA. N. Kirienko
A. N. Kirienko
IMI. A. Myasnikova
I. A. Myasnikova
BKB. A. Kanevsky
B. A. Kanevsky
PSP. V. Sorokin
P. V. Sorokin
The activity of the antimetabolic drug Riamilovir (Triazavirin®) was studied on a model of SARS-CoV-2 infection on Syrian hamsters. Infectious process was caused by the intranasal administration of the virus accumulated in the Vero-B culture with a concentration of 4.25×104 TCID50, in a volume of 26 µl/hamster. The effects of the drug at a dose of 20 mg/kg intraperitoneally daily in the midst of the infectious process were traced to accelerate the clearance of the virus in the lungs, prevent body weight loss and the severity of pulmonary edema, as well as preserve the mass of the spleen. The protective effects of Riamilovir on the structure of the lungs and brain are shown, it is suggested that the drug has the ability to penetrate the blood-brain barrier. It was concluded that Riamilovir has antiviral activity against SARS-CoV-2.

2 April 2024 in Bulletin of the Russian Military Medical Academy
Verified
Journal Article
Open access
PDF file
MKMarat A. Karamullin
Marat A. Karamullin
SCSergey V. Chepur
Sergey V. Chepur
ISIgor M. Samokhvalov
Igor M. Samokhvalov
ASAleksey N. Shutko
Aleksey N. Shutko
ASAleksey B. Seleznev
Aleksey B. Seleznev
ЧСЧеховских Юрий Сергеевич
Чеховских Юрий Сергеевич
The provision of state guarantees to citizens with medical care is achieved by compliance with clinical recommendations by medical organizations. However, acute diseases (conditions) caused by excess radiation were excluded from the relevant pathologies for the development of appropriate clinical recommendations. The current events increase the relevance of acute radiation pathology for the healthcare system and determine the high risk of such cases among the personnel of radiation-hazardous facilities and population. The necessity of developing national clinical guidelines for the prevention, diagnosis, treatment, and rehabilitation of acute radiation injury victims is substantiated. Based on an analytical review of the databases of NEB, PubMed, and Medline for 1970 to 2023 on the problem of prevention, diagnosis, treatment, and rehabilitation of individuals exposed to excess radiation and analysis of the regulatory framework governing the process of creating clinical recommendations in the Russian Federation on the provision of medical care to victims of acute radiation injuries, the main terms and their definitions relevant to acute radiation pathology were formulated, which must be unified when developing clinical recommendations. The basic classification of acute radiation lesions is presented, systematizing the variety of possible clinical forms of diseases (conditions) and their etiopathogenetic variants based on the characteristics of the types of ionizing radiation sources and individual characteristics of the conditions of acute radiation exposure. Variants of working clinical classifications of acute radiation lesions based on the generalization of the experience in the country and the world on the systematization of acute radiation pathology were determined. In general, the expediency of developing a group of clinical recommendations for the prevention, diagnosis, treatment, and rehabilitation of acute radiation injuries, covering all the various current clinical forms of diseases caused by excess (uncontrolled, unregulated, emergency) exposure, is justified. The task of determining the current list of diseases (conditions) and groups of diseases (conditions) caused by excessive human exposure in the dose range that can lead to the development of acute radiation lesions is of practical importance both for departmental medicine and the country’s healthcare system.